Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research report sent to investors on Monday, Marketbeat reports. The brokerage issued a buy rating and a $25.00 target price on the stock.

Several other analysts have also commented on BBNX. Baird R W raised Beta Bionics to a “hold” rating in a report on Thursday, February 20th. Leerink Partners initiated coverage on shares of Beta Bionics in a report on Monday. They set an “outperform” rating and a $28.00 target price for the company. Piper Sandler initiated coverage on shares of Beta Bionics in a research note on Monday. They issued an “overweight” rating and a $26.00 target price for the company. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective for the company. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $24.83.

Beta Bionics Stock Performance

Shares of BBNX opened at $20.60 on Monday. Beta Bionics has a fifty-two week low of $20.00 and a fifty-two week high of $24.50.

Insiders Place Their Bets

In other news, insider Mike Mensinger purchased 33,350 shares of the stock in a transaction dated Friday, January 31st. The shares were purchased at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. The trade was a 129.92 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. This represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.